Sino Biopharmaceutical Ltd (HK:1177)
:1177
Want to see HK:1177 full AI Analyst Report?
Top Page
Sino Biopharmaceutical
(1177)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$5.50
â–¼(-8.33% Downside)
Action:Reiterated
Date:05/03/26
The score is primarily supported by solid financial performance, especially strong gross profitability and improved free cash flow. It is meaningfully weighed down by weak technicals (price below key moving averages with negative MACD) and a demanding valuation (high P/E with only a modest dividend yield).
Positive Factors
Strong cash generation
Free cash flow rebounded in 2025 with FCF/net income near 0.82, showing reliable cash conversion from reported earnings. Durable cash generation supports sustained R&D investment, working capital needs and debt service, improving long-term financial flexibility and resilience.
Negative Factors
Rising leverage
A meaningful year-over-year increase in debt-to-equity reduces financial flexibility and raises interest and refinancing exposure. If profitability does not recover, higher leverage could constrain capital allocation for R&D or M&A and elevate solvency risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Free cash flow rebounded in 2025 with FCF/net income near 0.82, showing reliable cash conversion from reported earnings. Durable cash generation supports sustained R&D investment, working capital needs and debt service, improving long-term financial flexibility and resilience.
Read all positive factors
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$92.38B
Dividend Yield1.4%
Average Volume (3M)114.93M
Price to Earnings (P/E)42.8
Beta (1Y)0.88
Revenue Growth10.20%
EPS Growth30.38%
CountryHK
Employees24,379
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.20
Shares Outstanding18,745,367,000
10 Day Avg. Volume98,005,928
30 Day Avg. Volume114,926,811
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.44Price Target Upside40.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.24
Revenue Forecast (FY)HK$35.91B
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medi...
How the Company Makes Money
Sino Biopharmaceutical primarily makes money by selling proprietary and in-licensed prescription drugs in China. Revenue is mainly generated from (1) product sales of branded pharmaceuticals to hospitals and other healthcare providers (a key chann...
Sino Biopharmaceutical Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
64
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.57B | 31.83B | 28.87B | 26.20B | 26.03B | 26.86B |
| Gross Profit | 24.99B | 26.13B | 23.53B | 21.21B | 21.54B | 21.53B |
| EBITDA | 6.11B | 7.26B | 6.11B | 6.98B | 6.69B | 19.87B |
| Net Income | 3.87B | 2.34B | 3.50B | 2.33B | 2.54B | 14.61B |
Balance Sheet | ||||||
| Total Assets | 74.89B | 76.04B | 65.41B | 63.60B | 64.06B | 60.54B |
| Cash, Cash Equivalents and Short-Term Investments | 19.82B | 22.56B | 14.60B | 14.12B | 16.92B | 15.79B |
| Total Debt | 11.96B | 16.08B | 9.78B | 12.58B | 13.98B | 12.12B |
| Total Liabilities | 29.12B | 33.32B | 22.63B | 25.43B | 26.12B | 22.81B |
| Stockholders Equity | 33.37B | 30.68B | 31.96B | 30.47B | 29.75B | 30.29B |
Cash Flow | ||||||
| Free Cash Flow | 2.89B | 7.59B | 5.22B | 4.36B | 4.56B | 3.47B |
| Operating Cash Flow | 3.16B | 9.29B | 6.62B | 6.07B | 6.27B | 5.37B |
| Investing Cash Flow | -7.29B | -12.41B | -1.71B | -756.98M | -4.07B | -2.52B |
| Financing Cash Flow | 1.58B | 4.16B | -6.32B | -6.55B | -3.19B | -3.23B |
Sino Biopharmaceutical Technical Analysis
Negative
6.00
Price Trends
5.80
Negative
6.16
Negative
6.85
Negative
Market Momentum
-0.15
Positive
33.91
Neutral
6.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1177, the sentiment is Negative. The current price of 6 is above the 20-day moving average (MA) of 5.50, above the 50-day MA of 5.80, and below the 200-day MA of 6.85, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 33.91 is Neutral, neither overbought nor oversold. The STOCH value of 6.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1177.
Sino Biopharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$48.93B | 6.33 | 38.42% | 0.95% | 95.27% | 304.20% | |
73 Outperform | HK$38.67B | ― | 25.67% | ― | 16.65% | 0.87% | |
64 Neutral | HK$138.02B | 145.72 | 4.82% | ― | 38.55% | ― | |
55 Neutral | HK$92.38B | 42.77 | 11.03% | 1.40% | 10.20% | 30.38% | |
53 Neutral | HK$105.93B | -43.30 | -14.26% | ― | 44.03% | -108.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$39.90B | -256.36 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1177
Sino Biopharmaceutical
5.17
1.04
25.12%
HK:1801
Innovent Biologics
79.40
23.50
42.04%
HK:1530
3SBio
19.28
-1.40
-6.78%
HK:9926
Akeso, Inc.
115.00
27.10
30.83%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.22
36.72%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
71.15
27.65
63.56%
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical Plans Board Changes Ahead of 2026 AGM
Apr 29, 2026
Sino Biopharmaceutical has announced planned board changes at its 2026 annual general meeting, with executive director Tian Zhoushan stepping down from the board due to an internal reallocation of responsibilities while retaining his management ro...
Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate
Apr 29, 2026
Sino Biopharmaceutical has called its next annual general meeting for 17 June 2025 in hybrid format, combining an in-person session in Hong Kong with an online e-voting platform to facilitate broader shareholder participation. The agenda includes ...
Sino Biopharmaceutical Bolsters Leadership for Global Clinical Development
Apr 28, 2026
Sino Biopharmaceutical has strengthened its senior medical leadership by appointing Dr. Kang Xiaoyan as Chief Medical Officer, with responsibility for global clinical development and collaborations for innovative drugs across all therapeutic areas...
Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026
Apr 21, 2026
Sino Biopharmaceutical’s wholly owned unit LaNova Medicines has showcased new preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the American Association for Cancer Research Annual Meeting 2026, underscoring its push int...
Sino Biopharm Wins China Approval for New Alveolar Soft Part Sarcoma Therapy
Apr 20, 2026
Sino Biopharmaceutical announced that its subsidiary’s drugs Benmelstobart, an anti-PD-L1 monoclonal antibody, and Anlotinib, a multi-targeted tyrosine kinase inhibitor, have been approved in China as a combination therapy for advanced or un...
Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck
Apr 19, 2026
Sino Biopharmaceutical announced that its subsidiary LaNova Medicines presented preliminary clinical data at a major cancer research conference for MK-2010/LM-299, an investigational PD-1/VEGF tetravalent bispecific antibody for advanced solid tum...
Sino Biopharm Advances CLDN18.2 ADC With First Patient Dosed in Global Phase III Gastric Cancer Trial
Apr 15, 2026
Sino Biopharmaceutical said its subsidiary LaNova Medicines has enrolled the first patient in a Phase III registrational trial of tecotabart vedotin, an antibody-drug conjugate targeting CLDN18.2, as a first-line, chemotherapy-free combination wit...
Sino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial
Apr 9, 2026
Sino Biopharmaceutical announced that its subsidiary Hangzhou Hygieia Biomedical has enrolled the first U.S. patient in a Phase II clinical trial of Kylo-11, an siRNA drug targeting the LPA gene for patients with atherosclerotic cardiovascular dis...
Sino Biopharm Wins Early Greater Bay Area Nod for Naldemedine in Opioid-Induced Constipation
Apr 9, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured early approval in the Guangdong-Hong Kong-Macao Greater Bay Area to market Naldemedine, an innovative, orally administered selective peripheral opioid receptor antagonist for ...
Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205
Apr 8, 2026
Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing has secured U.S. FDA clearance for an investigational new drug application for TQB3205, an oral pan-KRAS inhibitor for advanced malignant tumors. The molecule is designed to bind multipl...
Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure
Mar 30, 2026
Sino Biopharmaceutical has completed its acquisition of 100% equity interest in Hygieia, which becomes an indirect wholly owned subsidiary and will be fully consolidated into the group’s financial statements. The transaction consideration is...
Sino Biopharm Buys HK$27 Million in Shares for Award Scheme
Mar 27, 2026
Sino Biopharmaceutical has disclosed a new share purchase under its restricted share award scheme, a long-term incentive program adopted to align selected participants with shareholder interests. The board, led by chairwoman Theresa Y Y Tse, retai...
Sino Biopharm lifts profit on surging innovative drug sales in 2025
Mar 26, 2026
Sino Biopharmaceutical reported a solid set of 2025 results, with revenue rising 10.3% year on year to RMB31.83 billion and gross margin edging up to 82.1%, reflecting the growing weight of higher-value products. The group’s focus on innovat...
Sino Biopharm Proposes HKD 0.05 Final Dividend for 2025
Mar 26, 2026
Sino Biopharmaceutical Limited has proposed a final ordinary cash dividend of HKD 0.05 per share for the financial year ended 31 December 2025, with shareholder approval scheduled for 17 June 2026. The stock will trade ex-dividend on 24 June 2026,...
Sino Biopharmaceutical to Rebrand English Stock Short Name and Website
Mar 26, 2026
Sino Biopharmaceutical Limited will change its English stock short name on the Hong Kong Stock Exchange from “SINO BIOPHARM” to “SBP GROUP” effective 9:00 a.m. on 31 March 2026, while its Chinese stock short name and stock ...
Sino Biopharmaceutical Wins MSCI ESG Rating Upgrade to AA on Green and Social Push
Mar 23, 2026
Sino Biopharmaceutical has been upgraded from A to AA in MSCI ESG Ratings, highlighting its leadership in environmental, social, and governance practices among global pharmaceutical peers. The group’s ESG governance is anchored in its “...
Sino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial
Mar 17, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has secured approval from China’s National Medical Products Administration to begin clinical trials of TRD221, a first-in-class complement protein modulator injection for ...
Sino Biopharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Sino Biopharmaceutical Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider whether to recommend a final d...
Sino Biopharm Reports Breakthrough Phase III Success for IDH1 Inhibitor in Biliary Tract Cancer
Mar 12, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported positive Phase III results for TQB3454, an IDH1 inhibitor developed as a national Category 1 innovative drug for advanced biliary tract cancer with IDH1 mutations. The trial ...
Sino Biopharm Wins NMPA Nod to Trial Pan-KRAS Cancer Drug TQB3205
Mar 11, 2026
Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration to begin clinical trials of TQB3205, an orally administered pan-KRAS inhibitor for advanced malignant tum...
Sino Biopharm Grants Sanofi Global Rights to First-in-Class JAK/ROCK Drug Rovadicitinib
Mar 3, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has signed an exclusive global license agreement with a Sanofi subsidiary for the development, manufacturing, and commercialization of its first-in-class oral JAK/ROCK inhibitor, rovadici...
Sino Biopharm Wins China Approval for First-in-Class Myelofibrosis Drug
Mar 1, 2026
Sino Biopharmaceutical has secured Chinese marketing approval for rovadicitinib tablets, branded Anxu, a first-in-class dual JAK/ROCK small-molecule inhibitor for first-line treatment of intermediate-2 or high-risk myelofibrosis and related condit...
Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug
Feb 15, 2026
Sino Biopharmaceutical has secured Chinese regulatory approval for a new indication of its Category 1 innovative PD-L1 inhibitor benmelstobart injection, marketed as Andewei, as maintenance therapy after chemoradiotherapy in patients with unresect...
Sino Biopharm Completes Phase III Enrollment for Next-Gen HER2-Low Breast Cancer Drug
Feb 9, 2026
Sino Biopharmaceutical has completed patient enrollment for a randomized, open-label Phase III trial of TQB2102, its independently developed HER2 bispecific antibody-drug conjugate for HER2-low recurrent or metastatic breast cancer. The company po...
Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment
Feb 8, 2026
Sino Biopharmaceutical’s subsidiary LaNova Medicines has completed patient enrollment in a Phase III registrational trial of tecotabart vedotin (LM-302), an antibody-drug conjugate targeting CLDN18.2 for third-line and later treatment of CLD...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.